» Articles » PMID: 26183542

Synthesis of New Oxadiazole Derivatives As α-glucosidase Inhibitors

Overview
Journal Bioorg Med Chem
Specialties Biochemistry
Chemistry
Date 2015 Jul 18
PMID 26183542
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Oxadiazole derivatives (6-28) having hydrazone linkage, were synthesized through condensation reaction between benzohydrazide 5 with various benzaldehydes. The oxadiazoles derivatives (6-28) were evaluated for their α-glucosidase inhibitory activity. The IC50 values for inhibition activity vary in the range between 2.64 ± 0.05 and 460.14 ± 3.25 μM. The IC50 values were being compared to the standard acarbose (IC50=856.45 ± 5.60 μM) and it was found that compounds 6-9, 12, 13, 16, 18, 20, 22-28 were found to be more active than acarbose, while other compounds showed no activity. Structure-activity relationship (SAR) studies suggest that oxadiazole benzohydrazones (6-28) inhibitory potential is dependent on substitution of the N-benzylidene part. Compound 18 (IC50=2.64 ± 0.05 μM), which has trihydroxy substitution at C-2', C-4', and C-5' on N-benzylidene moiety, recorded the highest inhibition activity that is three-hundred times more active than the standard drug, acarbose (IC50=856.45 ± 5.60 μM). Compound 23 (IC50=34.64 ± 0.35 μM) was found to be the most active among compounds having single hydroxyl substitution. Shifting hydroxyl from C-2' to C-4' (6) and C-3' (7) reduces inhibitory activity significantly. Compounds with chlorine substituent (compounds 16, 28, and 27) showed potent activities but lower as compared to hydroxyl analogs. Substituent like nitro or methyl groups at any position suppresses enzyme inhibition activity. This reveals the important presence of hydroxyl and halo groups to have enzyme inhibitory potential.

Citing Articles

1,3,4-Oxadiazole Scaffold in Antidiabetic Drug Discovery: An Overview.

Gupta O, Chawla G, Pradhan T Mini Rev Med Chem. 2024; 24(20):1800-1821.

PMID: 38644715 DOI: 10.2174/0113895575298181240410041029.


A Review on the Development of Novel Heterocycles as α-Glucosidase Inhibitors for the Treatment of Type-2 Diabetes Mellitus.

Patel P, Shah D, Bambharoliya T, Patel V, Patel M, Patel D Med Chem. 2024; 20(5):503-536.

PMID: 38275074 DOI: 10.2174/0115734064264591231031065639.


Bacterial Tyrosinase Inhibition, Hemolytic and Thrombolytic Screening, and In Silico Modeling of Rationally Designed Tosyl Piperazine-Engrafted Dithiocarbamate Derivatives.

Zahoor A, Hafeez F, Mansha A, Kamal S, Anjum M, Raza Z Biomedicines. 2023; 11(10).

PMID: 37893112 PMC: 10603954. DOI: 10.3390/biomedicines11102739.


In-vitro high-throughput library screening-Kinetics and molecular docking studies of potent inhibitors of α-glucosidase.

Ali M, Malik K, Zaidi A, Farooq U, Bukhari S, Majeed Z PLoS One. 2023; 18(6):e0286159.

PMID: 37390110 PMC: 10313066. DOI: 10.1371/journal.pone.0286159.


Evaluation and molecular modelling of bis-Schiff base derivatives as potential leads for management of diabetes mellitus.

Daoud S, Thiab S, Jazzazi T, Al-Shboul T, Ullah S Acta Pharm. 2023; 72(3):449-458.

PMID: 36651543 DOI: 10.2478/acph-2022-0019.